Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49,633,071
-
Number of holders
-
128
-
Total 13F shares, excl. options
-
34,931,958
-
Shares change
-
+5,015,740
-
Total reported value, excl. options
-
$1,072,410,439
-
Value change
-
+$72,943,477
-
Put/Call ratio
-
31.76%
-
Number of buys
-
80
-
Number of sells
-
-63
-
Price
-
$30.7
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q4 2016
188 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q4 2016.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 128 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34,931,958 shares
of 49,633,071 outstanding shares and own 70.38% of the company stock.
Largest 10 shareholders include ADAGE CAPITAL PARTNERS GP, L.L.C. (5,686,668 shares), FMR LLC (3,459,319 shares), WELLINGTON MANAGEMENT GROUP LLP (2,368,538 shares), VANGUARD GROUP INC (2,327,187 shares), ORBIMED ADVISORS LLC (2,275,825 shares), JANUS CAPITAL MANAGEMENT LLC (2,212,313 shares), STATE STREET CORP (1,946,098 shares), Redmile Group, LLC (1,290,140 shares), Partner Fund Management, L.P. (1,143,688 shares), and AMERICAN CENTURY COMPANIES INC (950,419 shares).
This table shows the top 128 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.